IPCA Laboratories Limited has informed the Exchange about Transcript of Conference Call held on 12th August, 2025
IPCALAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ipca Labs reported a mixed Q1 FY26 performance. Domestic formulations grew ~10% with market share rising to 2.08% (from 2.01%), maintaining 16th rank in IPM as per IQVIA. Export branded formulations grew 10% to Rs. 124 crores, generics grew 15% to Rs. 326 crores, and API grew 12%. Standalone EBITDA margin improved to 23.82% (from 22.22%), but consolidated EBITDA margin dipped slightly to 18.39% (from 18.52%) due to Unichem weakness — Unichem lost US market share on 4 key products, and faced Asia/Brazil declines plus Rs. 22 crores in one-time provisions (Euro fluctuation and Ireland facility closure). Standalone net profit rose 26% to Rs. 262 crores; consolidated net profit up 18% to Rs. 234 crores. Management revised full-year consolidated EBITDA margin guidance to ~75 bps improvement (from earlier 100 bps), while standalone margin guidance of ~1.5% improvement was retained. Topline growth guidance unchanged at 9-10%.
Mildly negative for near-term sentiment given consolidated margin guidance cut and Unichem underperformance, though strong standalone performance and improving US pipeline (4 products launched, $15-16M visibility, 4-5 more launches expected this year) provide medium-term positives. Shareholders should watch Unichem's recovery in coming quarters and synergy benefits expected to flow through in FY27.